<DOC>
	<DOCNO>NCT01365650</DOCNO>
	<brief_summary>This open label , three way study participant symptomatic allergic rhinitis . The follow 3 treatment administer subject dose period 1 , 2 3 , respectively : - Treatment A : Single intranasal dose 30 mg ketorolac tromethamine ( one 15 mg spray nostril ) Day 1 Period 1 . - Treatment B : Single intranasal dose oxymetazoline hydrochloride follow single intranasal dose 30 mg ketorolac tromethamine ( one 15 mg spray nostril ) 30 minute later Day 1 Period 2 . - Treatment C : Seven day treatment intranasal fluticasone propionate ( Periods 2 3 ) follow single intranasal dose 30 mg ketorolac tromethamine ( one 15 mg spray nostril ) Day 1 Period 3 . Subjects remain resident Clinical Unit Day 1 morning Day 2 period washout period 2 7 day period . A post study medical perform within 7 day Period 3 . The objective study : - To assess pharmacokinetics ( PK ) intranasal ketorolac participant symptomatic allergic rhinitis . - To assess effect single dose intranasal oxymetazoline hydrochloride pharmacokinetics tolerability intranasal ketorolac participant symptomatic allergic rhinitis . - To assess effect chronic administration fluticasone propionate bioavailability tolerability intranasal ketorolac participant symptomatic allergic rhinitis .</brief_summary>
	<brief_title>Study Assess Absorption Tolerability Intranasal Ketorolac Tromethamine Assess Effects Oxymetazoline Hydrochloride Fluticasone Propionate Absorption Tolerability Intranasal Ketorolac Tromethamine Participants With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>Male female volunteer , age 18 65 year inclusive Participant history allergic rhinitis treatment require least 3 day 7 within last 3 month . Subjects symptomatic allergic rhinitis currently use therapy find ineffective may include Participant otherwise consider exhibit general good health , opinion Investigator Participants may know medical condition consider `` stable '' expect interfere study outcome adversely affected involvement study . This determined Investigator time screen follow : A prestudy physical examination clinically significant abnormality Vital sign within normal range outside normal range deem clinically significant opinion Investigator An electrocardiogram ( ECG ) clinically significant abnormality Full medical history Participant bilateral patent nasal airways screen assess Investigator Participant body mass index ( BMI ) 19 29 kg/m2 Female participant child bear potential : Must negative urine pregnancy test prior entry study Must breast feed All female participant child bear potential male participant female partner child bear potential must consent use medically acceptable method contraception ( oral implant contraceptive hormone combine use barrier contraception , condom diaphragm spermicidal agent , intrauterine device , menopausal [ define last menstrual period &gt; 12 month ago ] surgical sterilization ) throughout study period minimum 4 week 1 full menstrual cycle prior inclusion Participant must able provide write informed consent Participant 's prestudy clinical laboratory finding within normal range outside normal range deem clinically significant opinion Investigator Glomerular filtration rate &gt; 75 mL/minute calculate use CockroftGault calculation creatinine clearance Any known allergy sensitivity ketorolac tromethamine , oxymetazoline hydrochloride , fluticasone propionate formulation ingredient Any history coexisting nasal polyp , NSAID sensitivity asthma Daily use intranasal decongestant medication Allergic reaction aspirin NSAIDs Current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment AEs Use nonprescribed drug 72 hour prior study drug administration study . Paracetamol use allow within 24 hour prior Day 1 period . NSAIDs restrict least 3 day 5 halflives , whichever longer , prior dose Day 1 Period 1 , must use throughout study . Current prescribe medication discontinue prior entry study study participation , unless know interact ketorolac per product information ( injectable ) Any suspicion rhinitis medicamentosa ( chronic daily use topical decongestant ) Use monoamine oxidase inhibitor 14 day prior study entry Positive serum test human immunodeficiency virus ( HIV ) hepatitis B C screen Positive serum alcohol test screen entry study Positive urine drug screen nonprescribed drug abuse ( DOA ) screen entry study Clinically significant abnormality screen laboratory test History cocaine use Concurrent use ritonavir potent CYP3A4 inducer inhibitor . Blood donation within 30 day begin study participation Active peptic ulcer disease , gastrointestinal bleeding perforation , history peptic ulcer disease gastrointestinal bleeding Anemia due unexplained known gastrointestinal bleeding Renal impairment risk renal failure due volume depletion . History asthma chronic pulmonary disorder , exception childhood asthma asymptomatic asthma , assess individually Principal Investigator Current tobacco use past history smoking &gt; = 5 packyears within last 5 year A history clinically significant , unstable medical problem , opinion Investigator would interfere study participation Participation another investigational drug study within 30 day study entry , 5 time halflife investigational drug , whichever longer Positive test Helicobacter pylorus ( H. pylorus ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>